70 results about "Neointimal hyperplasia" patented technology

Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

Devices and methods for reducing, eliminating, preventing, suppressing, or treating tissue responses to hemostatic devices e.g., biological sealants or vascular procedures are disclosed. The invention employs a combination of resorbable, biocompatible matrix materials and a variety of therapeutic agents, such as antiproliferatives or antibiotics, applied to a vascular puncture or incision to achieve hemostasis following diagnostic or interventional vascular catheterizations and to treat neointimal hyperplasia and stenosis. A matrix of a material such as collagen provides a reservoir of a therapeutic agent such as rapamycin (sirolimus) and its derivatives and analogs for delivery at a tissue site at risk for vasculoproliferation, infection, inflammation, fibrosis or other tissue responses.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

A stent according to the present invention incorporates an intraluminal scaffold for initial relief of stenoses or for providing support within bodily lumens, such as blood vessels, of children and adults. The scaffold minimizes flow disturbances in a stented region of a bodily lumen by the use of a strut having a transitional lumen surface, thereby limiting the potential for the development of neointimal hyperplasia and subsequent restenosis, and lessening the potential for early and late thrombosis formation and dislodgement. Any stent for use in any application can be initially manufactured with the strut shape of the current invention. Alternatively, the shape of the struts of existing stents can be modified during a post-processing procedure after fabrication thereby making the invention applicable to all stent designs presently available.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

The invention belongs to the field of medical apparatus and relates to a biodegradable stent with laminated coatings. The stent comprises a stent main body with a supporting role and at least two layers selected from a medicine coating, an endothelial cell growth promotion layer and a developing control layer; the main body material of the stent is a biodegradable polymer with higher mechanical strength; after implanted into a pathological position, the stent has strong supporting force and can play a role of supporting a pathological blood vessel in a short time; the developing control layer can help a doctor accurately observe the position and the expansion consistency of the stent in the operation so as to prevent adverse events, such as displacement, instant collapse, and the like from happening; medicines for restricting neointimal hyperplasia in the medicine coating can prevent restenosis of the blood vessel after the stent is implanted for a short time; and the endothelial cell growth promotion layer can promote endothelial cells to grow on the surface of the stent to wrap the stent in the vascular endothelium so as to prevent degradable fragments of the stent from falling into the blood to cause embolism.

Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and/or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

Devices and methods for the treatment of heart conditions, hypertension, and other medical disorders are described. For example, this document describes devices and methods for treating atrial fibrillation by performing thoracic vein ablation procedures, including pulmonary vein myocardium ablation. In some embodiments, the ablation is performed in coordination with the delivery a pharmacological agent that can abate the formation of tissue stenosis or neointimal hyperplasia caused by the ablation. Additionally, in some embodiments, particulate matter, such as thrombus or crystalline drug compounds, created during the ablation is captured and removed from the patient using devices and methods provided herein. Further, devices and methods for non-thermal methods of causing cell death, such as tissue suction and tissue stretching, are also described.

The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate) to inhibit the biological activity of the PDGFR.

A stent having a drug eluting formulation has three components: 1) Anti-neointimal hyperplasia or anti-restenosis agent 2) Main polymer 3) Additive polymer

The anti-neointimal hyperplasia or anti-restenosis agent includes, but not limited to, Paclitaxel, Taxol, Rapamycin, Tacrolimus, Actinomycin D, Methotrexate, Doxorubicin, cyclophosphamide, and 5-fluorouracil, 6-mercapatopurine, 6-thioguanine, cytoxan, cyclosporine, cytarabinoside, cis-platin, chlorambucil, busulfan, and any other drug that can inhibit cell proliferation, and combinations thereof. The main polymer includes, but not limited to, polystyrene, parylene and polyurethane. The additive polymer includes, but not limited to, polyethylene glycol capped with diisocyanate moiety (NCO-PEG).

9.0 g of parylene, 0.6 g of tacrolimus, 0.4 g of NCO-PEG and 0.01 g of triethylene amine were dissolved in 90 g of tetrahydrofuran. The resulting mixture was heated at 40° C. for 30 minutes and cooled to room temperature. To the solution was added 0.1 g of pH 8.0 aqueous solution and mixed thoroughly. The resulting solution is applied to bare metal stents for coating.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and/or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

The invention provides a preparation method of a silk fibroin anticoagulant material. The preparation method comprises the following steps: (S1) mixing a silk fibroin solution and polyethylene glycol diamine with a cross-linking agent for carrying out a reaction, then carrying out dialysis, and drying to obtain a polyethylene glycol diamine cationized silk fibroin material; (S2) dipping the polyethylene glycol diamine cationized silk fibroin material into a hirudin solution to obtain the silk fibroin anticoagulant material. Compared with the prior art, the preparation method provided by the invention protects a functional group at a thrombin bonding region from being affected by the reaction so as to prevent the influence on a structural domain bonded with the thrombin, and also can enable hirudin to be bonded onto the polyethylene glycol diamine cationized silk fibroin by means of an ionic bond with a stronger bonding force, thus achieving the effect of stably giving play to anticoagulation; therefore, the obtained silk fibroin anticoagulant material has an obvious function of inhibiting the activity of the thrombin, and is especially applied to prevention of the neointimal hyperplasia and postoperative thrombus formation of artificial blood vessels.

Methods of using interleukin-1 (IL-1) antagonists to prevent or treat restenosis and other neointimal hyperplasia conditions, including atherosclerosis, vascular access dysfunction, hypertension and related vascular diseases are provided.